Molecular Profiling for Liver Cancer
Next-generation sequencing (NGS) and genomic analysis to identify actionable mutations and guide precision therapy in HCC.
Understanding Molecular Profiling in HCC
Precision oncology through comprehensive genomic analysis of liver tumors.
Molecular profiling uses next-generation sequencing (NGS) to analyze tumor DNA and identify genetic alterations that drive hepatocellular carcinoma (HCC). This approach enables personalized treatment by matching patients with targeted therapies and clinical trials based on their tumor's unique molecular signature.
Key technologies include whole-exome sequencing (WES), targeted gene panels (50–500 genes), and RNA sequencing for fusion detection. Profiling reveals mutations in driver genes, copy number variations, tumor mutational burden (TMB), and microsatellite instability (MSI).
Approximately 40% of HCC patients have actionable genomic alterations, with TERT, TP53, and CTNNB1 being the most frequently mutated genes. Molecular data guides therapy selection and predicts treatment response.
Key Driver Genes in HCC
TERT promoter: 60% (early event)
TP53: 30–50% (poor prognosis)
CTNNB1: 30% (Wnt/β-catenin pathway)
ARID1A/ARID2: Chromatin remodeling
Molecular Profiling Workflow
From biopsy to actionable genomic insights
Tissue Acquisition
Sample: FFPE tumor block or fresh biopsy
Requirement: ≥20% tumor content
Quality Check: H&E staining and pathologist review
DNA/RNA Extraction
Method: Column-based or magnetic bead kits
Yield: Minimum 50–100 ng DNA
QC: Qubit and TapeStation analysis
Library Preparation & Sequencing
Panel: Targeted (e.g., 500-gene) or WES
Depth: >500x for tumor, >200x for normal
Platform: Illumina NovaSeq or similar
Bioinformatics & Reporting
Analysis: Variant calling, CNV, TMB, MSI
Therapy Matching: FDA-approved and trial options
Report: 7–14 days turnaround
Actionable Genomic Alterations in HCC
Therapeutically targetable mutations and pathways
Clinical Applications of Molecular Profiling
Transforming HCC management through precision diagnostics
Targeted Therapy Selection
Match patients to FDA-approved therapies and clinical trials based on genomic profile.
- 40% have ≥1 actionable alteration
- Improves progression-free survival
- Avoids ineffective treatments
- Guides combination strategies
Prognostic Stratification
Risk stratification using molecular subtypes and mutation burden.
- TP53 mutation = poor prognosis
- CTNNB1 = better survival
- TMB-H predicts immunotherapy response
- Integrates with BCLC staging
Resistance Monitoring
Serial profiling to detect acquired resistance mechanisms.
- Track MET amplification post-sorafenib
- Identify RAS/MAPK reactivation
- Guide second-line therapy switch
- Combine with ctDNA monitoring
Leading Molecular Profiling Platforms
Validated NGS solutions for clinical and research use
| Platform | Gene Panel | Turnaround | Key Features |
|---|---|---|---|
| FoundationOne CDx | 324 genes | 10–14 days | FDA-approved, TMB/MSI included |
| Tempus xT | 648 genes + RNA | 9–12 days | Whole transcriptome, immune profiling |
| Caris MI Profile | 592 genes | 8–10 days | IHC + NGS integration |
| Guardant360 TissueNext | 500+ genes | 7–10 days | Tissue-informed, high sensitivity |
Clinical Impact
Treatment Change Rate: 25–30% of patients receive new therapy
PFS Benefit: Median 5.2 vs 2.8 months (targeted vs standard)
Cost-Effectiveness: Reduces unnecessary systemic therapy
Scientific References
Peer-reviewed studies supporting molecular profiling in HCC
- Harding, J.J., et al. (2021). Comprehensive genomic analysis of hepatocellular carcinoma. Nature.
- Abou-Alfa, G.K., et al. (2023). Biomarker-driven therapy in HCC. JCO Precision Oncology.
- Llovet, J.M., et al. (2024). Molecular classification of HCC. The Lancet Oncology.
- Zhu, A.X., et al. (2024). FGFR inhibitors in HCC. Cancer Discovery.
Ready for Molecular Profiling?
Access comprehensive NGS testing through our global network of CLIA/CAP-certified laboratories.